![](/img/cover-not-exists.png)
Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)
Romero-Laorden, Nuria, Lozano, Rebeca, Jayaram, Anuradha, López-Campos, Fernando, Saez, Maria I., Montesa, Alvaro, Gutierrez-Pecharoman, Ana, Villatoro, Rosa, Herrera, Bernardo, Correa, Raquel, RoseroLanguage:
english
Journal:
British Journal of Cancer
DOI:
10.1038/s41416-018-0123-9
Date:
August, 2018
File:
PDF, 1.80 MB
english, 2018